On Friday, FDA Granted Accelerated Approval To Sanofi's Tzield (Teplizumab-mzwv) To Delay Decline In Endogenous (Own) Insulin Production In Children Aged 8 To 17 Years Recently Diagnosed With Stage 3 Type 1 Diabetes

뉴스 본문을 불러오고 있어요.

On Friday, FDA Granted Accelerated Approval To Sanofi's Tzield (Teplizumab-mzwv) To Delay Decline In Endogenous (Own) Insulin Production In Children Aged 8 To 17 Years Recently Diagnosed With Stage 3 Type 1 Diabetes | 웨이프 WAPE

On Friday, FDA Granted Accelerated Approval To Sanofi's Tzield (Teplizumab-mzwv) To Delay Decline In Endogenous (Own) Insulin Production In Children Aged 8 To 17 Years Recently Diagnosed With Stage 3 Type 1 Diabetes

기사 요약

관련 종목

댓글 —